WO2011010316A1 - Compositions pharmaceutiques d'irbésartan - Google Patents

Compositions pharmaceutiques d'irbésartan Download PDF

Info

Publication number
WO2011010316A1
WO2011010316A1 PCT/IN2009/000411 IN2009000411W WO2011010316A1 WO 2011010316 A1 WO2011010316 A1 WO 2011010316A1 IN 2009000411 W IN2009000411 W IN 2009000411W WO 2011010316 A1 WO2011010316 A1 WO 2011010316A1
Authority
WO
WIPO (PCT)
Prior art keywords
cellulose
composition
pharmaceutical composition
irbesartan
calcium
Prior art date
Application number
PCT/IN2009/000411
Other languages
English (en)
Inventor
Bandi Parthasaradhi Reddy
Pothireddy Venkateswar Reddy
Muppidi Vanaja Kumari
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to PCT/IN2009/000411 priority Critical patent/WO2011010316A1/fr
Publication of WO2011010316A1 publication Critical patent/WO2011010316A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to the stable pharmaceutical composition
  • the stable pharmaceutical composition comprising irbesartan or pharmaceutically acceptable salts thereof, alone or in combination with hydrochlorothiazide, and optionally one or more additional excipients.
  • Irbesartan a compound having the chemical name 2-butyl-3-[p-(o-1/-/- tetrazol-5-ylphenyl)benzyl]-1 ,3-diazaspiro[4.4]non-1-en-4-one, is a potent, long- acting angiotensin Il receptor is described in US Patent No.5, 270, 317.
  • Irbesartan is commercially available as 75mg, 150mg, or 300mg tablets, which are sold under the trade name AVAPRO.
  • the combination composition of irbesartan and hydrochlorothiazide is commercially available as 150/12.5 mg, 300/12.5mg, or 300/25 mg tablets, which are sold under the trade name AVALIDE.
  • US patent No. 5,994,348 describes a pharmaceutical composition which comprising about 20 to 70% irbesartan and about 2 to 33% hydrochlorothiazide based on total weight and composition being free povidone and poloxamer.
  • EP patent No. 167,461 describes oral pharmaceutical formulation of irbesartan in cellactose 80° and/or spary dried lactose is used as filling agent, prepared by wet granulation method with alcohol as wetting agent.
  • EP Patent Application No.1 ,806, 130 describes a solid pharmaceutical formulation which contains irbesartan hydrochloride and optionally hydrochlorothiazide, mannitol, low-substituted hydroxypropylcellulose and at least one lubricant selected from macrogol, talc and hydrogenated castor oil.
  • EP Patent Application No. 1 ,750,862 describes a composition which contains greater than 70% w/w irbesartan, a binder and a surfactant.
  • US Patent Application No. 2005/271720 describes a composition which contains 75% w/w irbesartan.
  • an object of the present invention is to provide the pharmaceutical formulation of irbesartan, having small weight, good dissolution, good flow property, reliable and robust pharmaceutical composition, which enable to have a formulation without any difficulty.
  • Another object of the present invention is to provide the pharmaceutical formulation of irbesartan in combination with hydrochlorothiazide, having small tablet, good dissolution, good flow property, reliable and robust oral solid pharmaceutical composition, which enable to have a formulation without any difficulty.
  • a pharmaceutical composition which comprises about 65% to about 85% irbesartan or pharmaceutically acceptable salts thereof, about 3% to about 40% microcrystalline cellulose or mannitol, about 0.25% to about 10% polyvinylpyrrolidone or hydroxy propyl cellulose, about 1 % to about 15% carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone of the total weight of the pharmaceutical composition, and optionally one or more additional excipients.
  • the pharmaceutical composition of the present invention has been found to have small tablet, good dissolution, good flow property, reliable and robust pharmaceutical formulation in comparison with other pharmaceutical compositions.
  • the pharmaceutical composition of the present invention which comprises about 71 % to about 74% irbesartan or pharmaceutically acceptable salts thereof, about 12% to about 25% microcrystalline cellulose or mannitol, about 0.5% to about 7% polyvinylpyrrolidone or hydroxy propyl cellulose, and about 2% to about 10% calcium carboxymethyl cellulose or carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone of the total weight of the pharmaceutical composition, and optionally one or more additional excipients.
  • Excipient selection depends on various factors, such as, the choice of active ingredient percentage, the objectives of the pharmaceutical formulation development and method of manufacture. The foremost property an excipient must possess is compatibility with active ingredients.
  • the pharmaceutical composition is oral solid dosage forms.
  • the pharmaceutical composition may be for example, in the form of a tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
  • the pharmaceutical composition is in the form of a tablet and a capsule.
  • the capsule may contain powder, compressed powder or granules.
  • the oral solid pharmaceutical composition is in the form of a tablet.
  • the additional excipients may be a filler agent, a disintegrant agent, a binder, a glidant and a lubricant.
  • the filler includes microcrystalline cellulose, mannitol, dibasic calcium phosphate, calcium carbonate, lactose, magnesium carbonate, magnesium oxide, lactose anhydrous, isomalt, sorbitol or mixtures thereof and more preferably microcrystalline cellulose and/or mannitol.
  • the lubricants includes magnesium stearate, calcium stearate, stearic acid, a salt of stearic acid, talc, sodium stearyl fumarate, glyceryl behenate, magnesium silicate, magnesium trisilicate, macrogol, talc, hydrogenated castor oil or mixtures thereof and more preferably magnesium stearate and/or calcium stearate.
  • the disintegratrants includes carboxymethyl cellulose calcium, croscarmellose sodium, starch, sodium starch glycolate, crospovidone, carboxymethylcellulose sodium, magnesium aluminium silicate or mixtures thereof and more preferably carboxymethyl cellulose calcium and/or croscarmellose sodium.
  • the glidant may be for example colloidal anhydrous silica, talc or mixtures thereof and more preferably colloidal anhydrous silica.
  • the binder includes polyvinylpyrrolidone k-30, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose (low- substituted), starch or mixtures thereof and more preferably polyvinylpyrrolidone k-30 and/or hydroxypropyl cellulose.
  • the coating agent includes hydroxypropyl methyl cellulose, polyvinyl alcohols, hydroxypropyl cellulose, macrogols or mixtures thereof and more preferably hydroxypropyl methyl cellulose and/or polyvinyl alcohols.
  • the coloring agent includes titanium dioxide, red iron oxide, yellow iron oxide, black iron oxides and mixture thereof.
  • ingredients such as stabilizers, antioxidants and antiadherants, conventionally used for pharmaceutical formulations may also be included in the present formulation.
  • the preferred embodiment of the invention is suitable for forming irbesartan tablet which comprising in parts by weight from about 65% to about 85% irbesartan or pharmaceutically acceptable salts thereof, from about 3% to about 40% microcrystalline cellulose or mannifol, from about 0.25% to about 10% polyvinylpyrrolidone or hydroxy propyl cellulose, from about 0.5% to about 10% carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone, from about 0.125% to about 2% colloidal anhydrous silica, from about 0.25% to about 5% calcium stearate, from about 1.5% to about 3.5%.
  • additional excipient/s may be used.
  • the additional excipients include pharmaceutical lubricants, disintegrators, binders, glidants, fillers or mixtures thereof.
  • the process for preparing the pharmaceutical composition which comprises mixing about 65% to about 85% irbesartan or pharmaceutically acceptable salts thereof, about 3% to about 40% microcrystalline cellulose or mannitol, about 0.25% to about 10% polyvinylpyrrolidone or hydroxy propyl cellulose, blend about 1% to about 15% carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone of the total weight of the pharmaceutical composition, and optionally one or more additional excipients.
  • the pharmaceutical compositions prepared according to process of the invention is oral solid dosage forms.
  • the oral solid pharmaceutical composition prepared according to process of the invention may be for example, in the form of a tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
  • the oral solid pharmaceutical composition is prepared in the form of a tablet.
  • the pharmaceutical process of the present invention are physically stable to pharmaceutical unit operations such as compression, thereby making pharmaceutical composition of the present invention amenable to pharmaceutical compounding operations, such as for example, tabletting.
  • the tablet compositions are prepared by the process of direct compression, wet granulation or slugging, more preferably wet granulation.
  • the tablet may be also optionally coated with a coating agent.
  • the pharmaceutical composition which comprises about 65% to about 85% irbesartan or pharmaceutically acceptable salts thereof in combination with hydrochlorothiazide, about 3% to about 40% microcrystalline cellulose or mannitol, about 0.25% to about 10% polyvinylpyrrolidone or hydroxyl propyl cellulose, about 1% to about 15% carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone of the total weight of the pharmaceutical composition, and optionally one or more additional excipients.
  • the pharmaceutical composition of the present invention has been found to have small tablet, good dissolution, good flow property, reliable and robust pharmaceutical formulation in comparison with other pharmaceutical compositions.
  • the pharmaceutical composition of the present invention which comprises about 71% to about 74% irbesartan or pharmaceutically acceptable salts thereof in combination with hydrochlorothizide, about 12% to about 25% microcrystalline cellulose or mannitol, about 0.5% to about 7% polyvinylpyrrolidone or hydroxy propyl cellulose, about 2% to about 10% calcium carboxymethyl cellulose or dibasic calcium phosphate or crospovidone of the total weight of the pharmaceutical composition, and optionally one or more additional excipients.
  • Excipient selection depends on various factors, such as, the choice of active ingredient percentage, the objectives of the pharmaceutical formulation development and method of manufacture. The foremost property an excipient must possess is compatibility with active ingredients.
  • the pharmaceutical composition is oral solid dosage forms.
  • the pharmaceutical composition may be for example, in the form of a tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
  • the pharmaceutical composition is in the form of a tablet and a capsule.
  • the capsule may contain powder, compressed powder or granules.
  • the oral solid pharmaceutical composition is in the form of a tablet.
  • the additional excipients may be a filler agent, a disintegrant agent, a binder, a glidant and a lubricant.
  • the filler includes microcrystalline cellulose, mannitol, dibasic calcium phosphate, calcium carbonate, lactose, magnesium carbonate, magnesium oxide, lactose anhydrous, isomalt, sorbitol or mixtures thereof and more preferably microcrystalline cellulose and/or mannitol.
  • the lubricants includes magnesium stearate, calcium stearate, stearic acid, a salt of stearic acid, talc, sodium stearyl fumarate, glyceryl behenate, magnesium silicate, magnesium trisilicate, macrogol, talc, hydrogenated castor oil or mixtures thereof and more preferably magnesium stearate and/or calcium stearate.
  • the disintegratrants includes carboxymethyl cellulose calcium, croscarmellose sodium, starch, sodium starch glycolate, crospovidone, carboxymethylcellulose sodium, magnesium aluminium silicate or mixtures thereof and more preferably carboxymethyl cellulose calcium and/or croscarmellose sodium.
  • the glidant may be for example colloidal anhydrous silica, talc or mixtures thereof and more preferably colloidal anhydrous silica.
  • the binder includes polyvinylpyrrolidone k-30, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose (low- substituted), starch or mixtures thereof and more preferably polyvinylpyrrolidone k-30 and/or hydroxypropyl cellulose.
  • the coating agent includes hydroxypropyl methyl cellulose, polyvinyl alcohols, hydroxypropyl cellulose, macrogols or mixtures thereof and more preferably hydroxypropyl methyl cellulose and/or polyvinyl alcohols.
  • the coloring agent includes titanium dioxide, red iron oxide, yellow iron oxide, black iron oxides and mixture thereof.
  • ingredients such as stabilizers, antioxidants, and antiadherants, conventionally used for pharmaceutical formulations may also be included in the present formulation.
  • the preferred embodiment of the invention is suitable for forming irbesartan and hydrochlorothiazide tablet which comprising in parts by weight from about 65% to about 85% irbesartan or pharmaceutically acceptable salts thereof, from about 1% to about 10% hydrochlorothiazide, from about 3% to about 40% microcrystalline cellulose or mannitol, from about 0.25% to about 10% polyvinylpyrrolidone or hydroxy propyl cellulose, from about 0.5% to about 10% carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone, from about 0.125% to about 2% colloidal anhydrous silica, from about 0.25% to about 5% calcium stearate, from about 1.5% to about 4% opadry.
  • additional excipient/s may be used.
  • the additional excipients include pharmaceutical lubricants, disintegrators, binders, glidents, fillers or mixtures thereof.
  • the process for preparing the pharmaceutical composition which comprises mixing about 65% to about 85% irbesartan or pharmaceutically acceptable salts thereof in combination with hydrochlorothiazide, about 3% to about 40% microcrystalline cellulose or mannitol, about 0.25% to about 10% polyvinylpyrrolidone or hydroxy propyl cellulose, blend about 1% to about 15% carboxymethyl cellulose calcium or dibasic calcium phosphate or crospovidone of the total weight of the pharmaceutical composition, and optionally one or more additional excipients.
  • the pharmaceutical composition prepared according to the process of the invention is oral solid dosage forms.
  • the oral solid pharmaceutical composition prepared according to the process of the invention may be for example, in the form of a tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
  • the oral solid pharmaceutical composition is prepared in the form of a tablet.
  • the pharmaceutical process of the present invention are physically stable to pharmaceutical unit operations such as compression, thereby making oral solid dosage of the present invention amenable to pharmaceutical compounding operations, such as for example, tabletting.
  • the tablet pharmaceutical compositions are prepared by the process of direct compression, wet granulation or slugging, more preferably wet granulation.
  • the tablet may be also optionally coated with a coating agent.
  • the pharmaceutical composition of the present invention may be used for the treatment of hypertension.
  • the tablets were prepared using the materials listed in table.
  • the tablets of example 1 and 2 were manufactured using the procedure which comprising the following steps: irbesartan, microcrystalline cellulose was done in a rapid mixer granulator and mixed for 5 to 20 minutes. Binder solution
  • the example demonstrates the dissolution properties of the tablet prepared in accordance with the invention.
  • the tablets of the irbesartan and commercially available irbesartan tablets were tested for in vitro drug release in 1000 ml of 0.1 N hydrochloric acid, USP-II apparatus and speed operating at 50 rpm.
  • the values for dissolution of irbesartan were greater than 80% in 10 minutes in irbesartan tablets.
  • the tablets were prepared using the materials listed in table.
  • the tablets of example 3 were manufactured using the procedure which comprising the following steps: irbesartan, microcrystalline cellulose was done in a rapid mixer granulator and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone in purified water) is added to contents of rapid mixer granulator and mixed to get dough mass. The dough mass was dried, and dried granules passed through #20.
  • Binder solution polyvinylpyrrolidone in purified water
  • the tablets were prepared using the materials listed in table.
  • the tablets of example 4 and 5 were manufactured using the procedure which comprising the following steps: irbesartan, hydrochlorothiazide, microcrystalline cellulose was done in a rapid mixer granulator and mixed for 5 to 20 minutes. Binder solution (polyvinylpyrrolidone in purified water) is added to contents of rapid mixer granulator and mixed to get dough mass. The dough mass was dried, and dried granules passed through #20.
  • Binder solution polyvinylpyrrolidone in purified water
  • the tablets were prepared using the materials listed in table.
  • the example demonstrates the dissolution properties of the tablet prepared in accordance with the invention.
  • the tablets of the irbesartan and hydrochlorothiazide and commercially available irbesartan and hydrochlorothiazide tablets were tested for in vitro drug release in 1000 ml of 0.1 N hydrochloric acid, USP-II apparatus and speed operating at 50 rpm.
  • the values for dissolution of irbesartan were greater than 80% in 10 minutes and hydrochlorothiazide were greater than 80% in 10 minutes.
  • the tablets were prepared using the materials listed in table.

Abstract

La présente invention concerne une composition pharmaceutique stable comprenant de l'irbésartan hautement dosé conjointement avec des excipients pharmaceutiquement acceptables. De plus, la composition peut contenir de l'hydrochlorothiazide.
PCT/IN2009/000411 2009-07-20 2009-07-20 Compositions pharmaceutiques d'irbésartan WO2011010316A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2009/000411 WO2011010316A1 (fr) 2009-07-20 2009-07-20 Compositions pharmaceutiques d'irbésartan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2009/000411 WO2011010316A1 (fr) 2009-07-20 2009-07-20 Compositions pharmaceutiques d'irbésartan

Publications (1)

Publication Number Publication Date
WO2011010316A1 true WO2011010316A1 (fr) 2011-01-27

Family

ID=43498826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000411 WO2011010316A1 (fr) 2009-07-20 2009-07-20 Compositions pharmaceutiques d'irbésartan

Country Status (1)

Country Link
WO (1) WO2011010316A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017052752A (ja) * 2015-09-11 2017-03-16 ニプロ株式会社 イルベサルタンを含有する医薬組成物及びその製造方法
CN107028912A (zh) * 2017-05-31 2017-08-11 珠海润都制药股份有限公司 一种厄贝沙坦胶囊的制备方法
CN109157527A (zh) * 2018-07-25 2019-01-08 珠海润都制药股份有限公司 一种厄贝沙坦胶囊及其制备方法
CN115531327A (zh) * 2021-06-29 2022-12-30 北京新领先医药科技发展有限公司 一种厄贝沙坦片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0747050A1 (fr) * 1995-06-07 1996-12-11 Bristol-Myers Squibb Company Compositions pharmaceutiques d'irbésartan
WO2005118166A2 (fr) * 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Composition pharmaceutique contenant de l'irbesartan
WO2008125388A1 (fr) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Compositions pharmaceutiques contenant de l'irbesartan

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0747050A1 (fr) * 1995-06-07 1996-12-11 Bristol-Myers Squibb Company Compositions pharmaceutiques d'irbésartan
WO2005118166A2 (fr) * 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Composition pharmaceutique contenant de l'irbesartan
WO2008125388A1 (fr) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Compositions pharmaceutiques contenant de l'irbesartan

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017052752A (ja) * 2015-09-11 2017-03-16 ニプロ株式会社 イルベサルタンを含有する医薬組成物及びその製造方法
CN107028912A (zh) * 2017-05-31 2017-08-11 珠海润都制药股份有限公司 一种厄贝沙坦胶囊的制备方法
CN109157527A (zh) * 2018-07-25 2019-01-08 珠海润都制药股份有限公司 一种厄贝沙坦胶囊及其制备方法
CN109157527B (zh) * 2018-07-25 2021-05-04 珠海润都制药股份有限公司 一种厄贝沙坦胶囊及其制备方法
CN115531327A (zh) * 2021-06-29 2022-12-30 北京新领先医药科技发展有限公司 一种厄贝沙坦片及其制备方法
CN115531327B (zh) * 2021-06-29 2024-04-30 北京新领先医药科技发展有限公司 一种厄贝沙坦片及其制备方法

Similar Documents

Publication Publication Date Title
CA2525874C (fr) Compositions pharmaceutiques a base de varenicline
TWI428151B (zh) 含有甘露醇或乳糖之固形製劑
KR20070046172A (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
US20120107397A1 (en) Pharmaceutical compositions of valsartan
CA2706292A1 (fr) Une formulation pharmaceutique stable renfermant du telmisartan et de l'hydrochlorothiazide
EP3606511B1 (fr) Composition pharmaceutique contenant du lenvatinib mesylate
US8481554B2 (en) Solid oral dosage forms of lamivudine
JP7346403B2 (ja) 難溶性の塩基性薬剤を含有する医薬組成物
WO2006134610A1 (fr) Composition pharmaceutique d'efavirenz presentant un profil de dissolution ameliore
WO2011010316A1 (fr) Compositions pharmaceutiques d'irbésartan
AU2012288632B2 (en) New (trimethoxyphenylamino)pyrimidinyl formulations
EP3860606B1 (fr) Composition pharmaceutique comprenant esylate ou tosylate de lenvatinib
WO2013023970A1 (fr) Composition pharmaceutique renfermant du 4-[4-[[4-chloro-3- (trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthylpyridine-2- carboxamide
EP2131817A2 (fr) Composition pharmaceutique de fumarate de quétiapine
WO2019076966A1 (fr) Comprimés comprenant de la tamsulosine et de la solifénacine
WO2008118031A1 (fr) Composition pharmaceutique comprenant du candésartan cilexétil et procédé de fabrication
KR20220028097A (ko) 다롤루타미드의 약제학적 조성물
EP2065035A1 (fr) Formules pharmaceutiques contenant de l'irbesartan
AU2002333235B2 (en) Pharmaceutical formulation containing an LTB4 antagonist
WO2023067522A1 (fr) Compositions pharmaceutiques
WO2023126973A1 (fr) Composition pharmaceutique stable d'elagolix
EP3843702A1 (fr) Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil
JP2005015363A (ja) 小型化クラリスロマイシン錠剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09847523

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09847523

Country of ref document: EP

Kind code of ref document: A1